RxDoctor Payments Data

Jared Bieniek, MD

Urology · Hartford, CTNPI 1982846457

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Acerus Pharmaceuticals Corporation at 52.8% of the total. Reporting peaked in 2022 at $4,790 and has fallen 90.1% since, to $472 in 2025.

$8,823in general payments, 2019–2025

Across 66 payments — averaging $133.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acerus Pharmaceuticals Corporation$5K
  • Boston Scientific$3K
  • Coloplast$1K
  • Olympus America Inc.$131
  • Antares Pharma, Inc.$100
  • Pfizer$29
  • plus $52 from 2 others

What the payments were for

  • Consulting fees$4,70053%
  • Speaking & faculty fees$1662%
  • Travel & lodging$1,44216%
  • Food & beverage$2,48628%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,823 in reported general payments places this provider in the 80th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$92,988
Medicare patients
301
Services billed
1,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron45$29,527
MyrbetriqMirabegron18$16,776
Testosterone64$8,572
Tamsulosin Hcl364$6,454
Tadalafil22$2,778
Potassium Citrate ErPotassium Citrate19$2,295
Finasteride157$1,490
Alfuzosin Hcl ErAlfuzosin Hcl65$1,316
Testosterone Cypionate43$1,308
Dutasteride11$261
Oxybutynin Chloride ErOxybutynin Chloride21$228
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$123
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$107
Cephalexin14$84
Meloxicam15$49

Paid to pharmacies, not to this prescriber.

Other urology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →